Mutation detection primer group of MEIOB gene, antisense oligonucleotide targeting mRNA of MEIOB gene, small molecule drug aiming at MEIOB protein and application of small molecule drug

The problem of detecting and inhibiting MEIOB gene mutations is solved by providing primer sets for detecting MEIOB gene mutations, antisense oligonucleotide molecules targeting mRNA of MEIOB gene transcription product, and small molecules targeting MEIOB proteins is achieved, and Effective solutions for idiopathic infertility and cancer treatment.

CN119082286APending Publication Date: 2024-12-06WUHAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411199868.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively detect and target MEIOB gene mutations, leading to idiopathic infertility and cancer treatment challenges. The abnormal MEIOB leads to stagnation of sperm development and high expression characteristics, and lacks effective inhibitory means.

Method used

Provides primer sets for detecting MEIOB gene mutations, antisense oligonucleotide molecules targeting mRNA of MEIOB gene transcription product, and small molecules targeting MEIOB proteins, respectively, for detecting mutation sites, inhibiting MEIOB expression and blocking sperm. Formulate, achieve contraception and targeted therapy.

Benefits of technology

Efficient detection of MEIOB gene mutations and blocking MEIOB protein function are achieved, which reduces sperm formation and tumor cell proliferation ability, and provides important clinically important contraceptive and treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082286A_ABST
    Figure CN119082286A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of gene detection and biological medicine, in particular to a MEIOB gene mutation detection primer group, an antisense oligonucleotide targeting mRNA of the MEIOB gene, a small molecule aiming at MEIOB protein, an analogue of the small molecule and application of the small molecule, and the found hMEIOB gene mutation site and the potential mutation site in the hMEIOB gene can be detected. The ASO molecule can bind to a transcription product of the MEIOB gene in a targeted manner to inhibit the expression of the transcription product. The MEIOB protein targeted chemical small molecule and the analogue thereof have the capability of inhibiting the combination of MEIOB and SPATA22, and can be used as a non-hormone male contraceptive. The small chemical molecule of the targeted MEIOB protein and the analogue thereof have the capability of inhibiting the protein level and cell proliferation of MEIOB in a tumor cell line with high expression of MEIOB, and can be used as a targeted drug for treating tumors with high expression of MEIOB.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical fields of a primer set for detecting a MEIOB gene mutation and an application thereof, an antisense oligonucleotide molecule targeting the mRNA of a MEIOB gene transcription product and an application thereof, a small molecule targeting the MEIOB protein and an application thereof, and in particular to a primer set for detecting a mutation of the MEIOB gene, an antisense oligonucleotide targeting its mRNA, and a small molecule drug targeting the MEIOB protein and an application thereof. Background Art

[0002] The precise completion of meiosis is crucial for the stable transmission of genetic information. In 2013, through the study of meiotic proteomics in mouse models, the inventor (Luo Mengcheng) first discovered a single-stranded DNA binding protein MEIOB (meiosis specific with OB domain) that is involved in the recombination of homologous chromosomes in the prophase of meiosis I. By studying its function, it was found that abnormal MEIOB can cause male sperm development to arrest at the prophase of meiosis I and early apoptosis of female follicles; with the progress of research on human meiosis-related proteins, it was discovered in 2014 that MEIOB was nominated as a new cancer antigen due to its high expression characteristics in cancer and may be used as a target for immunotherapy; in 2016, transcriptome analysis of testicular tissue from 19 testicular cancer patients confirmed that MEIOB belongs to extremely highly expressed testicular cancer-related genes (extremely highly expressed CT genes, EECTGs); in 2017, whole genome sequencing of members of the same family with azoospermia was performed, and MEIOB mutations were discovered for the first time as a genetic pathogenic factor; in 2019, some scholars found that familial primary ovarian insufficiency was associated with human MEIOB abnormalities; in 2020, a cohort of 25 people with idiopathic oligospermia or non-obstructive azoospermia was subjected to NGS (next-generation sequencing). Sequencing) analysis found that most people have abnormal hMEIOB gene sequences; in the same year, another study found that some patients carried hMEIOB pathogenic gene variants through exome sequencing of meiosis-related genes in a spermatogenesis arrest cohort of 147 people. Currently, multiple hMEIOB mutations have been analyzed, but the uncertainty of gene mutations is high, and new mutation patterns will appear in the future.

[0003] In summary, detecting the MEIOB gene sequence in infertile patients is of great clinical significance for clarifying the cause of idiopathic infertility and targeted treatment; targeted inhibition of MEIOB gene expression or protein function can block the spermatogenesis process and achieve a contraceptive effect. Summary of the invention

[0004] One of the purposes of the present invention is to provide a primer set for detecting MEIOB gene mutation and its application, which can detect the discovered hMEIOB gene mutation site and potential mutation site in the hMEIOB gene.

[0005] The second purpose of the present invention is to provide an antisense oligonucleotide molecule targeting the mRNA of the MEIOB gene transcription product and its application, which can target and bind to the transcription product of the hMEIOB gene to inhibit its expression. Its full thiolation modification improves the stability and half-life of the molecule, and the molecule itself is non-toxic and degradable.

[0006] The third object of the present invention is to provide a small molecule targeting MEIOB protein and its analogs and their applications, which can be used to block MEIOB function and sperm formation to achieve contraceptive effects, and can also be used to reduce the expression level of MEIOB protein in tumor cells and cell proliferation ability to achieve targeted therapy.

[0007] The scheme adopted by the present invention to achieve one of the purposes is: on the one hand, a primer set for detecting MEIOB gene mutation is provided, which can detect the discovered hMEIOB (human MEIOB gene) gene mutation site and the potential mutation site in the hMEIOB gene, including the following primer pairs:

[0008] The nucleotide sequences of the primer set for exon 1 are shown in SEQ ID NO.1 and SEQ ID NO.2;

[0009] The nucleotide sequences of the primer set for exon 2 are shown in SEQ ID NO.3 and SEQ ID NO.4;

[0010] The nucleotide sequences of the primer set for exon 3 are shown in SEQ ID NO.5 and SEQ ID NO.6;

[0011] The nucleotide sequences of the primer set for exon 4 are shown in SEQ ID NO.7 and SEQ ID NO.8;

[0012] The nucleotide sequences of the primer set for exon 5 are shown in SEQ ID NO.9 and SEQ ID NO.10;

[0013] The nucleotide sequences of the primer set for exon 6 are shown in SEQ ID NO.11 and SEQ ID NO.12;

[0014] The nucleotide sequences of the primer set for exon 7 are shown in SEQ ID NO.13 and SEQ ID NO.14;

[0015] The nucleotide sequences of the primer sets for exons 8 and 9 are shown in SEQ ID NO.15 and SEQ ID NO.16;

[0016] The nucleotide sequences of the primer set for exon 10 are shown in SEQ ID NO. 17 and SEQ ID NO. 18;

[0017] The nucleotide sequences of the primer set for exon 11 are shown in SEQ ID NO. 19 and SEQ ID NO. 20;

[0018] The nucleotide sequences of the primer set for exon 12 are shown in SEQ ID NO. 21 and SEQ ID NO. 22;

[0019] The nucleotide sequences of the primer set for exon 13 are shown in SEQ ID NO.23 and SEQ ID NO.24.

[0020] Preferably, the primer set can cover the entire exons of the human MEIOB gene and the introns at the ends of the exons.

[0021] The primer set can be used for PCR reaction to amplify different exon sequences of hMEIOB, and the different sequences can cover the entire exon of the hMEIOB gene and the intron at the end of each exon.

[0022] On the other hand, a kit for detecting human MEIOB gene mutation containing the primer set is provided.

[0023] Specifically, a kit for detecting non-obstructive azoospermia or premature ovarian insufficiency containing the primer set is provided.

[0024] The solution adopted by the present invention to achieve the second purpose is: on the one hand, an antisense oligonucleotide molecule targeting the mRNA of the transcription product of the MEIOB gene is provided, which is a single-stranded DNA with a nucleotide sequence of ATTTATCGTGCAGCCCAAAGT, a sequence length of 21bp, 3 locked nucleic acids at each end, and a fully thiolated modification.

[0025] Preferably, the antisense oligonucleotide molecule recognizes mRNA through base complementarity and inhibits the expression of MEIOB protein.

[0026] On the other hand, a method for reducing the mRNA content of the MEIOB gene in cells by co-incubating the antisense oligonucleotide molecule with a culture medium or by injecting the antisense oligonucleotide molecule into the testis is provided.

[0027] Specifically, an application of the antisense oligonucleotide molecule targeting the mRNA of the transcription product of the MEIOB gene is provided, and the mRNA content of the hMEIOB gene in the cell is reduced by co-incubating the antisense oligonucleotide molecule with the culture medium.

[0028] Alternatively, another application of the antisense oligonucleotide molecule targeting the mRNA of the MEIOB gene transcription product is provided, and the mRNA content of the mMEIOB gene (mouse MEIOB gene) in the mouse testis is reduced by testicular injection of the antisense oligonucleotide molecule, the administration method is local scrotal injection, the dosage is 0.33nmol / g, and the observation time is 72 hours.

[0029] Specifically, it is used to prepare a product for inhibiting the expression of mRNA, a transcription product of the MEIOB gene, or inhibiting the expression of the MEIOB protein.

[0030] The solution adopted by the present invention to achieve the third purpose is: a small molecule targeting MEIOB protein and its analogs, at least one of whose molecular structures is shown below:

[0031]

[0032] Preferably, the small molecule targeting MEIOB protein can inhibit the binding of MEIOB to SPATA22 by binding to MEIOB protein.

[0033] Preferably, the small molecules and analogs thereof targeting MEIOB protein bind reversibly to the MEIOB protein and can be rapidly dissociated from the surface of the MEIOB protein as the concentration decreases.

[0034] On the other hand, a use of the small molecule and its analogs targeting MEIOB protein is provided, and the production of sperm in the testicle is inhibited by oral administration or local subcutaneous injection of the small molecule and its analogs targeting MEIOB protein.

[0035] An application of the small molecule targeting MEIOB protein and its analogs is used to prepare a product that inhibits the binding of MEIOB and SPATA22 in cells or inhibits the production of sperm in testicles.

[0036] An application of the small molecule targeting MEIOB protein and its analogs is used for preparing contraceptive drugs.

[0037] An application of the small molecule targeting MEIOB protein and its analogs is used to prepare drugs for treating tumors with high MEIOB expression.

[0038] The present invention has the following advantages and beneficial effects:

[0039] The primer set provided by the present invention can amplify intron sequences containing 100 bp bases on both sides of the exon, so it can be used to detect the production of abnormal spliceosomes caused by intron mutations at the ends of exons. In addition to identifying all existing mutation types, it can also be used to detect new unknown mutations.

[0040] The (antisense oligonucleotide molecule targeting the mRNA of the transcription product of the MEIOB gene) ASO molecule provided by the present invention can target and bind to the transcription product of the MEIOB gene to inhibit its expression, and its full thiolation modification improves the stability and half-life of the molecule, and the molecule itself is non-toxic and degradable.

[0041] The MEIOB protein-targeted small molecule provided by the present invention has the ability to inhibit the binding of MEIOB to SPATA22, can prevent sperm production, and achieve a contraceptive effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 The results of RT-QPCR test to identify that ASO reduces the level of hMEIOB gene mRNA in cells;

[0043] Figure 2 The results of RT-QPCR test to identify that ASO reduces the mMEIOB gene mRNA level in mouse testis;

[0044] Figure 3 Live cell fluorescence imaging shows that small molecules targeting hMEIOB affect the binding of MEIOB and SPATA22;

[0045] Figure 4 HE staining of testicular tissue showed that small molecules targeting mMEIOB affected spermatogenesis in seminiferous tubules.

[0046] Figure 5 This is the result of sperm count in the cauda epididymis;

[0047] Figure 6 Results of Western Blot detection of MEIOB protein levels in HELA, SiHA, C33A, A2780, MD231, and THP-1 cell lines;

[0048] Figure 7 Western Blot analysis to identify small molecules targeting hMEIOB that reduce the level of MEIOB protein in C33A cells;

[0049] Figure 8 Grayscale results for Western Blot identification of small molecules targeting hMEIOB to reduce MEIOB protein levels in C33A cells;

[0050] Fig. 9 The results of identifying small molecules targeting hMEIOB for CCK8 to reduce the proliferation ability of C33A cells;

[0051] Fig.10 The results of different concentrations of small molecules targeting hMEIOB for CCK8 identification after 72 hours of addition to reduce the proliferation ability of C33A cells;

[0052] Fig.11 The results of identifying small molecules targeting hMEIOB for CCK8 to reduce the proliferation ability of A2780 cells;

[0053] Fig.12 The results of different concentrations of small molecules targeting hMEIOB for CCK8 identification on the reduction of A2780 cell proliferation ability after 72 hours of addition. DETAILED DESCRIPTION

[0054] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0055] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0056] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0057] Example 1

[0058] Identification of gene point mutations:

[0059] 1. Primer design. The genomic sequence of the human MEIOB gene was analyzed to locate each exon and the 100 bp intron sequences on both sides, and the exon containing the aforementioned introns on both sides was selected as the target sequence; the upstream and downstream primers were generated using Snapgene software to ensure that the annealing temperature of all primers was around 63°C, see Table 1.

[0060] Table 1 Primer sequence information

[0061]

[0062]

[0063]

[0064] 2. Peripheral blood genome extraction. Draw 0.5 mL of blood from the subject's vein, add 0.8 mL of normal saline and mix well, centrifuge at 10,000 rpm for 1 min at room temperature; remove the supernatant, keep 0.1 mL of precipitate, add 0.4 mL of TE buffer to resuspend the cells, add 5 μL of 10 mg / mL proteinase K and 50 μL of 10% SDS to lyse the cells, and digest overnight in a 37°C water bath; add 1 / 3 volume of saturated sodium chloride solution, mix thoroughly, let stand for 10 min, and centrifuge at 10,000 rpm for 10 min; take the supernatant to a new tube, add an equal volume of chloroform and mix thoroughly, centrifuge at 10,000 rpm for 10 min; aspirate the upper aqueous phase to a new tube, add 1 / 10 volume of 3M NaAc (pH 5.2) Mix well, add 0.7 times the volume of isopropanol and mix well, centrifuge at 10000 rpm for 5 min; remove the supernatant, add 0.5 mL of 70% ethanol to wash the isopropanol, invert and mix, centrifuge at 10000 rpm for 5 min, remove the supernatant and repeat once; open the lid to allow the ethanol to fully evaporate, add 50 μL of sterilized double distilled water, and fully dissolve at 55°C; use Nanodrop instrument to measure the DNA concentration, and then store at -20°C.

[0065] 3. PCR amplification of target sequence. The reaction system is 40 μL, add 20 μL of 2×Taq polymerase reaction premix, 100 ng of DNA template, 2 μL of 10 μM upstream and downstream primers, and appropriate amount of double distilled water (ddH2O), mix well, and use the following parameters for PCR amplification reaction: pre-denaturation at 95°C for 3 minutes, denaturation at 95°C for 30 seconds, annealing at 63°C for 30 seconds, extension at 72°C for 30 seconds, cycle 30 times, continue extension for 5 minutes after the cycle, and keep warm at 12°C.

[0066] 4. Target sequence gene sequencing. Obtain the target sequence through the gel recovery kit, and determine the purity and concentration of the plasmid DNA using a UV spectrophotometer; select the respective sequencing primers (the default is F) and perform DNA amplification according to Sanger's dideoxy chain termination method, send the reaction product to a capillary electrophoresis instrument for analysis, and determine the composition of the DNA sequence by detecting different fluorescent colors; use bioinformatics software such as Snapgene to edit and align the sequencing results to obtain accurate coding sequence information.

[0067] 5. DNA sequence comparison. Comparing the sequencing results with the standard nucleic acid information and existing mutation information (Table 2) can reveal whether the subject's MEIOB gene is normal, whether it conforms to the existing mutation, and whether there is a new type of gene mutation.

[0068] Table 2 Known mutation information

[0069]

[0070] Example 2

[0071] ASO molecules reduce the level of hMEIOB gene mRNA in cells:

[0072] 1. Construction of hMEIOB stable expression cell line. The hMEIOB mRNA was obtained from the testis, reverse transcribed into cDNA, and the full-length hMEIOB gene sequence was amplified and constructed into the pcDNA3.1 plasmid; to facilitate the observation of gene expression, the green fluorescent protein (GFP) coding sequence was fused to the end of hMEIOB; the sequenced recombinant plasmid was transfected into the U2OS cell line, and the cell line stably expressing hMEIOB was screened using 500 μg / mL of G418.

[0073] 2. ASO molecule synthesis. Based on the mRNA sequence of hMEIOB, a complementary ASO sequence with a length of 21 nucleotides was designed; an automated oligonucleotide synthesizer was used to gradually build the ASO chain by adding single nucleotides; the ASO was treated with a thiolation reagent and then purified to remove unreacted reagents and other impurities; it was purified by high-performance liquid chromatography (HPLC) and characterized by mass spectrometry to ensure that its quality and purity met the experimental requirements.

[0074] 3. Co-culture of ASO molecules with cells and identification of hMEIOB gene expression by RT-QPCR. The synthesized ASO molecules were co-cultured with the hMEIOB gene stably transfected cell line constructed above at a final concentration of 4 μM for 72 hours, and the cells were recovered to extract mRNA and reverse transcribed to obtain a PCR reaction template; the relative mRNA level of hMEIOB in the cells after the addition of ASO was detected by RT-QPCR reaction and the difference was statistically analyzed; the mRNA level of hMEIOB in U2OS cells decreased by 72% after the addition of ASO, indicating that ASO can effectively intervene in the expression of hMEIOB ( Figure 1 ).

[0075] Example 3

[0076] ASO molecules reduce the mRNA level of the mMeiob gene in mouse testis

[0077] 1. Mouse preparation: Select 6-8 week old C57BL / 6J male mice, weigh them, calculate the drug dosage (0.33 nmol / g), and anesthetize the mice by intraperitoneal injection.

[0078] 2. Testicular injection of ASO molecules. Squeeze the abdomen of the mouse to make the testicles return to the scrotum; use a microsyringe to draw up the ASO solution and inject the drug directly into the testicles through the scrotal skin; put the mouse back into the cage, wait for it to wake up, and then transfer the cage to the animal room to continue feeding for 72 hours.

[0079] 3. RT-QPCR identification of mMeiob gene expression. Extract mRNA from testicular tissue and reverse transcribe it into cDNA; detect the relative mRNA level of mMeiob in mouse testis after adding ASO by RT-QPCR reaction and statistically analyze the difference; the results showed that the relative mRNA level of mMeiob in mouse testis decreased after ASO (0.044±0.005vs.0.037±0.002)( Figure 2 ).

[0080] Example 4

[0081] Small molecules targeting MEIOB protein inhibit the interaction between MEIOB and SPATA22 in cells

[0082] 1. Construction of cell lines stably expressing MEIOB and SPATA22. pcDNA3.1 vectors expressing MEIOB protein fused with green fluorescent protein (GFP) and SPATA22 fused with red fluorescent protein (mCherry) were constructed respectively, and co-transfected into U2OS cell lines. Cell lines stably expressing the two fluorescent fusion proteins were screened by G418.

[0083] 2. Screening of small molecules targeting MEIOB protein. Through virtual screening, candidate small molecules were obtained, and small molecule compounds ZJH-I-OMe (CID_10847865), ZJH-I-OGer, ZJH-I-OEt, ZJH-I-OiPr, ZJH-I-OCD3, ZJH-I-OH, ZJH-I-HHG, ZJH-I-103-B, and ZJH-I-103-C were further synthesized.

[0084]

[0085]

[0086] Table 3 shows the names and affinity constants of the nine compounds.

[0087]

[0088]

[0089] The affinity constants (KD) of these 9 small molecule compounds were detected by biomembrane interference technology. The results showed that the KD values ​​of ZJH-I-OMe (CID_10847865) and ZJH-I-HHG were lower, indicating that they had higher affinity with MEIOB protein (Table 3). The following experiments selected ZJH-I-OMe (CID_10847865) for verification.

[0090] 3. Co-culture of small molecules with cells. CID_10847865 small molecules at a concentration of 40 μM were added to the culture medium and co-cultured with U2OS cells in a 37°C CO2 incubator for 48 hours.

[0091] 4. Fluorescence microscopy was used to detect cell interactions. The distribution of GFP protein and mCherry protein was observed under 488nm and 596nm excitation light, respectively. The fluorescence results showed that both MEIOB and SPATA22 could be localized in the nucleus in U2OS cells in the culture medium without small molecules. In the culture medium with small molecules, MEIOB was distributed in the cytoplasm, while SPATA22 was localized in the nucleus alone, suggesting that small molecules affect the binding of the two proteins ( Figure 3 ).

[0092] Example 5

[0093] Small molecules targeting MEIOB protein inhibit spermatogenesis in mouse testis

[0094] 1. Mouse preparation: Select 6-8 week old C57BL / 6J male mice, weigh them, and calculate the dosage (0.3 mg / 20 g) and frequency of administration (once every 2 days, 7 times in total).

[0095] 2. Small molecule scrotal injection: Use a microsyringe to draw up the small molecule premix (the drug is dissolved in 10 μL DMSO), pull up the mouse scrotal skin, and ensure that the solution is injected subcutaneously; put the mouse back into the cage and continue to feed it.

[0096] 3. Preparation of paraffin sections and HE staining of testicular tissue. Mice were killed by cervical dislocation, testicles were separated and fixed, paraffin tissue sections were prepared, and the tissues were stained by HE staining. After sealing, the structural changes of seminiferous tubules were observed under a microscope. After drug administration, hollow seminiferous tubules appeared in the testicles of mice ( Figure 4 ).

[0097] 4. Count sperm in the tail of epididymis. Separate the epididymis of mice and soak it in 1 mL PBS solution. Cut the tissue into pieces to fully release sperm. Take 10 μL of solution and add 90 μL PBS to dilute it. Take 10 μL of the dilution to the cell counting plate, cover it with a coverslip, heat it at 50°C for 5 minutes to stop sperm movement, and count sperm under a microscope. The number of sperm in the epididymis of mice after medication decreased ( Figure 5 ).

[0098] Example 6

[0099] Small molecules targeting MEIOB protein reduce the proliferation ability of tumor cells with high MEIOB expression

[0100] 1. Screening of tumor cell lines with high expression of MEIOB. Whole cell proteins of cervical cancer cell lines (HELA, SiHA, C33A), breast cancer cell lines (A2780, MD231) and leukemia cell line (THP-1) were collected, and the expression level of MEIOB protein was detected by Western Blot. The results showed that MEIOB was highly expressed in cervical cancer cell line C33A and breast cancer cell lines A2780 and MD231 ( Figure 6 ).

[0101] 2. Western Blot was used to detect the effect of small molecules on the expression level of MEIOB in cells. Small molecules of different concentrations were added to the culture medium and incubated with C33A cells in a 37°C CO2 incubator for 72 hours. The protein expression level of MEIOB in cells was detected by Western Blot. Western Blot results showed that the protein level of MEIOB in cells decreased with the increase of small molecule concentration, indicating that small molecules targeting MEIOB protein inhibited the protein expression level of MEIOB in C33A cell line ( Figure 7 , 8 ).

[0102] 3. CCK8 detection of cell proliferation. C33A and A2780 cells were inoculated in a 96-well plate and incubated in a 37°C CO2 incubator. After the cells adhered, small molecules of different concentrations were added to the culture medium and incubated with C33A and A2780 cells, respectively. The cells were removed at 0, 24, 48, 72, and 96 hours, 10 μL of CCK8 detection reagent was added to each well, and the culture was continued for 2 hours. The 450nm light absorption value was read with an enzyme reader. The CCK8 results showed that after the addition of small molecules targeting the MEIOB protein, the cell viability of C33A and A2780 cells decreased ( Figure 9-12 ).

[0103] The above is only a preferred embodiment of the present invention, which certainly cannot be used to limit the scope of rights of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and changes can be made without departing from the principle of the present invention, and these improvements and changes are also regarded as the protection scope of the present invention.

Claims

1. A primer set for detecting MEIOB gene mutation, characterized in that: It can detect the discovered hMEIOB gene mutation sites and potential mutation sites in the hMEIOB gene, including the following primer pairs: The nucleotide sequences of the primer set for exon 1 are shown in SEQ ID NO.1 and SEQ ID NO.2; The nucleotide sequences of the primer set for exon 2 are shown in SEQ ID NO.3 and SEQ ID NO.4; The nucleotide sequences of the primer set for exon 3 are shown in SEQ ID NO.5 and SEQ ID NO.6; The nucleotide sequences of the primer set for exon 4 are shown in SEQ ID NO.7 and SEQ ID NO.8; The nucleotide sequences of the primer set for exon 5 are shown in SEQ ID NO.9 and SEQ ID NO.10; The nucleotide sequences of the primer set for exon 6 are shown in SEQ ID NO.11 and SEQ ID NO.12; The nucleotide sequences of the primer set for exon 7 are shown in SEQ ID NO.13 and SEQ ID NO.14; The nucleotide sequences of the primer sets for exons 8 and 9 are shown in SEQ ID NO.15 and SEQ ID NO.16; The nucleotide sequences of the primer set for exon 10 are shown in SEQ ID NO. 17 and SEQ ID NO. 18; The nucleotide sequences of the primer set for exon 11 are shown in SEQ ID NO. 19 and SEQ ID NO. 20; The nucleotide sequences of the primer set for exon 12 are shown in SEQ ID NO. 21 and SEQ ID NO. 22; The nucleotide sequences of the primer set for exon 13 are shown in SEQ ID NO.23 and SEQ ID NO.

24.

2. An application of a primer set for detecting MEIOB gene mutation, characterized in that: Used in the preparation of products for diagnosing non-obstructive azoospermia or premature ovarian insufficiency.

3. An antisense oligonucleotide molecule targeting the mRNA of the MEIOB gene transcription product, characterized in that: It is a single-stranded DNA with a nucleotide sequence of ATTTATCGTGCAGCCCAAAGT, a sequence length of 21bp, 3 locked nucleic acids at each end, and a fully thiolated modification.

4. The antisense oligonucleotide molecule targeting the mRNA of the MEIOB gene transcription product according to claim 3, characterized in that: The antisense oligonucleotide molecules recognize mRNA through base complementarity, thereby inhibiting the expression of MEIOB protein or inhibiting the expression of mRNA, a transcription product of MEIOB gene.

5. An application of an antisense oligonucleotide molecule targeting mRNA of a MEIOB gene transcription product according to claim 3 or 4, characterized in that: Used to prepare products for inhibiting the expression of mRNA of MEIOB gene transcription product or inhibiting the expression of MEIOB protein.

6. Use of an antisense oligonucleotide molecule targeting the mRNA of the MEIOB gene transcription product according to claim 3 or 4, characterized in that: Used in the preparation of contraceptive drugs.

7. A small molecule targeting MEIOB protein and its analogs, characterized in that: Its molecular structure is at least one of the following:

8. The small molecule targeting MEIOB protein and its analogs according to claim 7, characterized in that: The small molecules and analogs thereof targeting MEIOB protein can inhibit the binding of MEIOB to SPATA22 by binding to MEIOB protein. The binding of the small molecules and analogs thereof targeting MEIOB protein to MEIOB protein is reversible and can be rapidly dissociated from the surface of MEIOB protein as the concentration decreases.

9. A use of a small molecule targeting MEIOB protein and its analogs according to claim 7 or 8, characterized in that: Used to prepare products that inhibit the binding of MEIOB to SPATA22 in cells or inhibit the production of sperm in testicles.

10. A use of a small molecule targeting MEIOB protein and its analogs according to claim 7 or 8, characterized in that: Used in the preparation of contraceptive drugs.

11. A use of a small molecule targeting MEIOB protein and its analogs according to claim 7 or 8, characterized in that: Used to prepare drugs for tumors with high MEIOB expression.